Fundraising Fox

Alcresta

Massachusetts, US · Delaware corporation · 4 known investors

alcresta.com ↗

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases. The company is based in Massachusetts and focuses on delivering novel enzymatic solutions within the biotechnology and pharmaceutical sector.

BiotechHealthtechMedical Devicesin /10674874

Founders & leadership

DO
Daniel OrlandoChief Executive Officer
JL
Jeremy LackDirector
SK
Stephen KraussDirector
TK
Tasos KonidarisExecutive Officer
JT
James TopperDirector
SD
Steve DubinDirector
MP
Martin PazExecutive Officer
RG
Robert GallottoExecutive Officer
DT
Daniel TasseExecutive Officer, Director
WS
William ScheinlerExecutive Officer
AM
Alexey MargolinDirector

Investors · 4

HealthQuest Capital✓ verifiedRedwood City
Bessemer Venture PartnersRedwood City · $5M – $100M
Frazier Life SciencesPalo Altovia James N. Topper · board
Third Rock VenturesreportedBoston · $100K – $5M

Reported raises · per SEC filings

Form D private placements
▶$10MraisedMar 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen KrausDirector
  • Anastasios KonidarisExecutive Officer, Director
  • William ScheinlerExecutive Officer
  • Alexey MargolinDirector
  • Todd CreechDirector
  • Steve DubinDirector
  • Daniel OrlandoExecutive Officer, Director
Offering amount
$20M
Amount sold
$10M
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJan 2019 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexey MargolinDirector
  • Steve DubinDirector
  • Anastasios KonidarisExecutive Officer, Director
  • William ScheinlerExecutive Officer
  • Stephen KrausDirector
  • Garheng KongDirector
Offering amount
$25M
Amount sold
$5M
First sale
Jan 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedSep 2017 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anastasios KonidarisExecutive Officer, Director
  • Stephen KrausDirector
  • Eric FirstExecutive Officer
  • Garheng KongDirector
  • William ScheinlerExecutive Officer
  • Steve DubinDirector
  • James TopperDirector
  • Alexey MargolinDirector
  • Daniel TasseExecutive Officer, Director
  • Martin PazExecutive Officer
  • James GamgortExecutive Officer
Offering amount
$35M
Amount sold
$10M
First sale
Sep 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50.9MraisedOct 2016 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeremy LackDirector
  • Stephen KraussDirector
  • Tasos KonidarisExecutive Officer
  • James TopperDirector
  • Steve DubinDirector
  • Martin PazExecutive Officer
  • Robert GallottoExecutive Officer
  • Daniel TasseExecutive Officer, Director
  • William ScheinlerExecutive Officer
  • Alexey MargolinDirector
Offering amount
$50.9M
Amount sold
$50.9M
Proceeds to insiders
$1M
First sale
Mar 2016
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news